However, this association may be confounded by indication bias and patient selection, as mTOR inhibitors are frequently prescribed for recipients with underlying comorbidities such as chronic kidney disease or CAV—conditions that themselves have been associated with poorer COVID-19 outcomes (32, 33). Here, MTOR is linked to chronic kidney disease.